Pacira BioSciences (PCRX) Cash & Equivalents (2010 - 2026)

Pacira BioSciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $144.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 49.12% year-over-year to $144.3 million; the TTM figure through Mar 2026 stood at $144.3 million (down 49.12% YoY), while the FY2025 annual figure was $158.5 million, down 42.72% from the prior year.
• Cash & Equivalents was $144.3 million for Q1 2026 at Pacira BioSciences, down from $158.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $300.5 million in Q2 2025 to a low of $35.5 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $172.1 million across 5 years, with a median of $153.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 84.32% in 2023, then jumped 417.8% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $104.1 million in 2022, then soared by 47.21% to $153.3 million in 2023, then jumped by 80.55% to $276.8 million in 2024, then tumbled by 42.72% to $158.5 million in 2025, then retreated by 8.98% to $144.3 million in 2026.
• The last three Cash & Equivalents figures came in at $144.3 million (Q1 2026), $158.5 million (Q4 2025), and $147.6 million (Q3 2025), per Business Quant data.